Business Description
Denali Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US24823R1059
Total Employee Number:
507Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 28.6 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -6 | |||||
3-Year EPS without NRI Growth Rate | -4.5 | |||||
3-Year FCF Growth Rate | -5.3 | |||||
3-Year Book Growth Rate | -5.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 26.36 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.38 | |||||
9-Day RSI | 47.41 | |||||
14-Day RSI | 50.13 | |||||
3-1 Month Momentum % | 18.77 | |||||
6-1 Month Momentum % | 14.91 | |||||
12-1 Month Momentum % | 73.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.28 | |||||
Quick Ratio | 9.28 | |||||
Cash Ratio | 8.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.7 | |||||
Shareholder Yield % | 0.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -50.64 | |||||
ROA % | -43.02 | |||||
ROIC % | -181.62 | |||||
3-Year ROIIC % | 225.04 | |||||
ROC (Joel Greenblatt) % | -440.91 | |||||
ROCE % | -50.45 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.05 | |||||
Price-to-Tangible-Book | 4.21 | |||||
EV-to-EBIT | -5.12 | |||||
EV-to-Forward-EBIT | 66.13 | |||||
EV-to-EBITDA | -5.26 | |||||
EV-to-Forward-EBITDA | 52.31 | |||||
EV-to-Forward-Revenue | 64.33 | |||||
EV-to-FCF | -6.68 | |||||
| Price-to-Net-Current-Asset-Value | 5.5 | |||||
| Price-to-Net-Cash | 5.79 | |||||
Earnings Yield (Greenblatt) % | -19.53 | |||||
FCF Yield % | -11.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DNLI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Denali Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.88 | ||
| Beta | 1.4072 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.19 | ||
| Volatility % | 49.07 | ||
| 14-Day RSI | 50.13 | ||
| 14-Day ATR ($) | 1.35527 | ||
| 20-Day SMA ($) | 24.992 | ||
| 12-1 Month Momentum % | 73.4 | ||
| 52-Week Range ($) | 12.58 - 27.3 | ||
| Shares Outstanding (Mil) | 158.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Denali Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Denali Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 106 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 19 days | ||
| General meeting for 2026 | 2026-06-03 10:00 | 19.35 (-3.06%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 20.41 (+6.19%) | ||
| Annual report for 2025 | 2026-02-26 | 22.29 (+3.19%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 22.29 (+3.19%) | ||
| Guidance call for 2026 | 2026-02-05 12:30 | 21.28 (-3.18%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-13 13:30 | 17.95 (+4.07%) | ||
| Jefferies Global Healthcare Conference | 2025-11-18 07:20 | 17.37 (-0.17%) | ||
| Guidance call for 2025 | 2025-11-12 08:40 | 17.58 (+12.84%) |
Show
Entries
Denali Therapeutics Inc Frequently Asked Questions
What is Denali Therapeutics Inc(DNLI)'s stock price today?
The current price of DNLI is $23.64. The 52 week high of DNLI is $27.30 and 52 week low is $12.58.
When is next earnings date of Denali Therapeutics Inc(DNLI)?
The next earnings date of Denali Therapeutics Inc(DNLI) is 2026-08-11 Est..
Does Denali Therapeutics Inc(DNLI) pay dividends? If so, how much?
Denali Therapeutics Inc(DNLI) does not pay dividend.
Guru Commentaries on NAS:DNLI
No articles.
Press Release
Articles on Denali Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers